Literature DB >> 6541867

Effect of amiodarone on left ventricular ejection and filling in hypertrophic cardiomyopathy as assessed by radionuclide angiography.

D D Sugrue, S Dickie, M J Myers, J P Lavender, W J McKenna.   

Abstract

Left ventricular (LV) function at rest was assessed by radionuclide angiography in 30 patients with hypertrophic cardiomyopathy (HC) before and during treatment with amiodarone (600 to 800 mg for 1 week, 200 to 400 mg/day thereafter) for an initial maintenance period of 1 month in 30 patients and 6 months in 12 patients. The reproduciblity of the measurements was assessed by performing control studies within 24 hours in 13 patients and at 1 to 6 months in 6 patients, and 95% confidence limits for spontaneous change were determined. There was a significant decrease in heart rate at 1 month (from 67 +/- 9 vs 61 +/- 9 beats/min, p less than 0.004) with no further decrease at 6 months. Systemic blood pressure did not change. After amiodarone therapy, for each of the measurements of LV function except peak ejection rate, there was no mean change and the number of patients in whom the values increased and decreased by more than the 95% confidence limits were approximately equal. Peak ejection rate showed a significant decrease at 1 month, but this effect was not maintained at 6 months; 4 of 6 patients who showed a significant decrease at 1 month were reevaluated at 6 months, and in all 4 the values had returned to control levels. These findings suggest that the 95% confidence limits for spontaneous change were not wide enough and that chronic oral amiodarone therapy does not alter radionuclide indexes of LV function at rest in patients with hypertrophic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6541867     DOI: 10.1016/s0002-9149(84)80143-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Hemodynamic effects of amiodarone during acute and chronic treatment in patients with recurrent sustained ventricular tachycardia.

Authors:  M Manz; W Jung; B Lüderitz
Journal:  Clin Investig       Date:  1992-05

2.  Radionuclide assessment of left ventricular function in hypertrophic cardiomyopathy.

Authors:  D D Sugrue; W J McKenna
Journal:  Postgrad Med J       Date:  1986-06       Impact factor: 2.401

Review 3.  Selegiline--an overview of its role in the treatment of Parkinson's disease.

Authors:  K Wessel; I Szelenyi
Journal:  Clin Investig       Date:  1992-05

4.  Haemodynamic effects of short term intravenous amiodarone for hypertrophic cardiomyopathy.

Authors:  A Branzi; C Rapezzi; P M Benenati; G Binetti; G Piovaccari; M Bacchi; R Roncuzzi; R Zannoli; B Magnani
Journal:  Br Heart J       Date:  1988-04

5.  Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population.

Authors:  F Cecchi; I Olivotto; A Montereggi; G Squillatini; A Dolara; B J Maron
Journal:  Heart       Date:  1998-04       Impact factor: 5.994

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.